What's holding back biotech M&A? SVB tracks a trend and calls a comeback
The dealmakers in biopharma have had some extra time on their hands in the first half of 2017. M&A has slowed considerably, but one prominent player in the field is keeping the faith that H2 will make up for the lag.
Silicon Valley Bank has put out its report on the first half of the year, and you can see from the chart below — which combines biotech IPOs and M&A — what I mean by a slowdown.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.